A small placebo-controlled trial has given senolytics something the longevity field needs: a signal of improvement in human disease, measured in liver tissue. It is encouraging evidence for a specific treatment in a specific illness, not evidence that people can take an anti-aging drug and live longer.
The study, published in Nature Metabolism on October 1, 2026, tested dasatinib plus quercetin, known as D+Q, in people with fibrotic metabolic dysfunction-associated steatohepatitis, or MASH.
A meaningful update to the senolytics story
In Whatever Happened to Senolytics?, we examined the gap between impressive animal experiments and limited human evidence. This trial adds a disease-related tissue outcome to that discussion. The important question is no longer just whether a treatment moves a laboratory marker. It is whether patients show a measurable improvement, and whether that improvement holds up in larger studies.
What the trial found
The single-centre Phase 2 study at Amsterdam University Medical Center randomized 31 participants; 27 completed it. Neither participants nor investigators knew who received D+Q or placebo. Treatment was intermittent over 21 weeks.
- Fibrosis improved by at least one stage without worsening MASH in approximately 47% of the D+Q group versus 7% of the placebo group.
- MASH resolution was reported in approximately 53% versus 7%.
- Single-nucleus RNA sequencing of liver biopsies showed reduced senescence-associated and fibrosis-associated gene signatures.
- Adverse events occurred more frequently with D+Q, approximately 82% versus 43%. Investigators described them as self-limiting.
These are the paper’s reported percentages, not a guarantee of benefit for an individual patient. Randomization helps separate treatment effects from other differences between groups, but this sample is too small to settle effectiveness or safety.
Why liver fibrosis matters
MASH is a form of fatty-liver disease involving inflammation and injury. Fibrosis means scar tissue has accumulated as the liver responds to repeated damage. More advanced scarring can interfere with the organ’s function.
A biopsy-based improvement in scarring is therefore clinically interesting. It reaches beyond a blood test that merely suggests biological activity. Even so, improved biopsy findings are not the same as demonstrating fewer cases of liver failure, fewer transplants or longer survival. Those outcomes require further evidence.
What senolytics are trying to do
Cellular senescence is a stress response in which cells stop dividing but remain alive and active. This can be useful, including as a defence against cancer. Persistent senescent cells, however, can release inflammatory signals that disturb surrounding tissue.
Senolytics aim to remove certain senescent cells by disrupting the mechanisms that keep them alive. Dasatinib is a prescription cancer medicine. Quercetin is a plant compound found in foods and sold in concentrated supplements. Combining them in a monitored clinical trial is very different from eating quercetin-containing foods or buying an online supplement protocol.
The RNA analysis examined gene activity in individual cell nuclei. It supports a biological explanation for the tissue findings, but changing a molecular signature does not by itself prove that every harmful senescent cell was removed.
What this does not establish
This was a small study at one centre in people with a particular liver disease. It does not demonstrate slower whole-body human aging or lifespan extension. Larger trials must establish how durable the response is, who benefits, and whether the balance of benefit and harm remains favourable.
Self-limiting adverse events in this study should not be read as proof that dasatinib is harmless. The drug can cause serious problems, including low blood-cell counts, bleeding and fluid retention. These results do not support self-treatment with D+Q or other senolytic protocols.
The defensible conclusion is narrower, and still valuable: targeting senescence has produced an encouraging randomized human disease signal that deserves replication.
Primary research
Koning and colleagues. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nature Metabolism, October 1, 2026. DOI: 10.1038/s42255-026-01643-4. PubMed record.